$1 Billion in Bids Expected for Mumbai-based Company

According to recent media reports, global private equity firms are reportedly preparing bids of about $1 billion for Bharat Serums and Vaccines (BSV).

On April 6, 2024, Manufacturing Today India reported that US-based Advent International acquired BSV in 2019 and is looking to sell the company.

Mumbai-based BSV is best known for its specialized products in women’s health, critical care, IUI-IVF, hormones, antibodies, and fungal infections. In FY 2023, its revenues were Rs 1,435 crore.